^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:Ibrance (palbociclib) (CDK4/6 inhibitor) +
    Verzenio (abemaciclib) (CDK4/6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Cancer Treat Res
    Title:

    Cyclin-dependent kinase 4/6 inhibitors in combination with fulvestrant for previously treated metastatic hormone receptor-positive breast cancer patients: A systematic review and meta-analysis of randomized clinical trials

    Published date:
    05/04/2020
    Excerpt:
    To compare the efficacy and safety profile of the combination of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and fulvestrant versus fulvestrant alone in previously treated patients with advanced hormone-receptor positive breast cancer. Use of abemaciclib, palbociclib, or ribociclib in combination with fulvestrant was significantly associated with longer PFS compared to use of fulvestrant alone...
    Secondary therapy:
    fulvestrant
    DOI:
    10.1016/j.ctarc.2020.100175
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A Prospective, Multi-center Real-world Study to Evaluate the Efficacy and Safety of Palbociclib or Abemaciclib in Combination With Endocrine Treatment(ET) in Patients with HR+HER2- Locally Advanced or Metastatic Breast Cancer

    Excerpt:
    ...Pathological examination confirmed HR-positive, HER2-negative breast cancer patients with local recurrence or metastasis evidence. ...
    Trial ID:
    ChiCTR2200057393